1) Lin DC, Xu L, Ding LW, Sharma A, Liu LZ, Yang H, Tan P, Vadgama J, Karlan BY, Lester J, Urban N, Schummer M, Doan N, Said JW, Sun H, Walsh M, Thomas CJ, Patel P, Yin D, Chan D, Koeffler HP.
Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers.
Proc. Natl. Acad. Sci. U.S.A. 110: 6109-14, 2013.
[Journal]
2) Duveau DY, Hu X, Walsh MJ, Shukla S, Skoumbourdis AP, Boxer MB, Ambudkar SV, Shen M, Thomas CJ.
Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors.
Bioorg. Med. Chem. Lett. 23: 682-6, 2013.
[Journal]
3) Mathews LA, Keller JM, Goodwin BL, Guha R, Shinn P, Mull R, Thomas CJ, de Kluyver RL, Sayers TJ, Ferrer M.
A 1536-Well Quantitative High-Throughput Screen to Identify Compounds Targeting Cancer Stem Cells.
J. Biomol. Screen. 17: 1231-42, 2012.
[Journal]
4) Johnson BC, Pauly GT, Rai G, Patel D, Bauman JD, Baker HL, Das K, Schneider JP, Maloney DJ, Arnold E, Thomas CJ, Hughes SH.
A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants.
Retrovirology. 9: 99, 2012.
[Journal]
5) Mott BT, Cheng KC, Guha R, Kommer VP, Williams DL, Vermeire JJ, Cappello M, Maloney DJ, Rai G, Jadhav A, Simeonov A, Inglese J, Posner GH, Thomas CJ.
A furoxan-amodiaquine hybrid as a potential therapeutic for three parasitic diseases().
Medchemcomm. 3: 1505-1511, 2012.
[Journal]
1) Beutler JA, Chung S, Jiang JK, Legrice SF, Thomas CJ, Wilson JA (submitted in 2011) Tropolone Compounds For Treating Or Preventing Retroviral Infection.
Patent pending: PCT/US2012/037208 (PC application).
2) FitzGerald D, Jiang JK, O'Shea JJ, Onda M, Pastan IH, Thomas CJ (submitted in 2010) Inhibition Of Antibody Responses To Foreign Proteins.
Patent pending: PCT/US2011/024382 (PC application).